Observations placeholder
Ranexa
Identifier
015686
Type of Spiritual Experience
Background
A description of the experience
Ranolazine, sold under the trade name Ranexa is a drug to treat angina that was first approved in 2006. Ranolazine is used to treat chronic angina.
“In clinical trials ranolazine increased QT interval in some patients and the FDA label contains a warning for doctors to beware of this effect in their patients.” The drug's effect on the QT interval is increased in the setting of liver dysfunction; thus it is contraindicated in persons with mild to severe liver disease.
Ranolazine was approved by the FDA in January 2006, for the treatment of patients with chronic angina as a second-line treatment in addition to other drugs. In 2007 the label was updated to make ranolazine a first-line treatment, alone or with other drugs. In April 2008 ranolazine was approved by the European EMEA for use in angina.
On Mar, 7, 2015: 1,705 people reported to have side effects when taking Ranexa. Among them, 28 people (1.64%) have Hallucination.
Time on Ranexa when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 73.33% | 0.00% | 20.00% | 0.00% | 6.67% | 0.00% | 0.00% |
Gender of people who have Hallucination when taking Ranexa :
| Female | Male | |
| Hallucination | 42.11% | 57.89% |
Age of people who have Hallucination when taking Ranexa :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Hallucination | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.67% | 13.33% | 80.00% |
On Mar, 11, 2015: 1,705 people reported to have side effects when taking Ranexa. Among them, 65 people (3.81%) have Death.